(0.25%) 5 144.25 points
(0.19%) 38 513 points
(0.35%) 17 908 points
(-0.55%) $83.39
(1.98%) $1.961
(0.07%) $2 348.80
(0.27%) $27.61
(0.85%) $929.95
(-0.20%) $0.933
(-0.26%) $11.00
(-0.30%) $0.798
(1.18%) $92.96
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 5.42%
@ $45.58
发出时间: 15 Feb 2024 @ 04:47
回报率: -2.93%
上一信号: Feb 14 - 22:30
上一信号:
回报率: 2.09 %
Live Chart Being Loaded With Signals
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally...
Stats | |
---|---|
今日成交量 | 439 929 |
平均成交量 | 696 560 |
市值 | 3.64B |
EPS | $0 ( 2024-02-15 ) |
下一个收益日期 | ( $-1.730 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -5.36 |
ATR14 | $0.0470 (0.11%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-18 | Crombez Eric | Sell | 142 | Common Stock |
2024-04-16 | Huizenga Theodore Alan | Sell | 14 | Common Stock |
2024-03-11 | Kassberg Thomas Richard | Sell | 11 509 | Common Stock |
2024-03-07 | Fust Matthew K | Sell | 2 550 | Common Stock |
2024-03-07 | Fust Matthew K | Sell | 2 145 | Common Stock |
INSIDER POWER |
---|
45.65 |
Last 99 transactions |
Buy: 915 632 | Sell: 371 334 |
音量 相关性
Ultragenyx Pharmaceutical 相关性
10 最正相关 | |
---|---|
GAINL | 0.862 |
ITMR | 0.852 |
DVCR | 0.847 |
AVEO | 0.845 |
ISNS | 0.842 |
VLYPP | 0.831 |
CHMA | 0.825 |
OPNT | 0.825 |
SUMR | 0.813 |
EDUT | 0.813 |
10 最负相关 | |
---|---|
SHSP | -0.9 |
BOCH | -0.891 |
XFOR | -0.833 |
GRCL | -0.833 |
ENPH | -0.827 |
RDHL | -0.82 |
THTX | -0.819 |
PTPI | -0.805 |
QTEK | -0.801 |
BLU | -0.801 |
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Ultragenyx Pharmaceutical 相关性 - 货币/商品
Ultragenyx Pharmaceutical 财务报表
Annual | 2023 |
营收: | $434.25M |
毛利润: | $389.04M (89.59 %) |
EPS: | $-8.25 |
FY | 2023 |
营收: | $434.25M |
毛利润: | $389.04M (89.59 %) |
EPS: | $-8.25 |
FY | 2022 |
营收: | $363.33M |
毛利润: | $335.01M (92.21 %) |
EPS: | $-10.12 |
FY | 2021 |
营收: | $351.41M |
毛利润: | $335.40M (95.44 %) |
EPS: | $-6.70 |
Financial Reports:
No articles found.
Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。